Ascending single dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of HKI-272 [neratinib] administered orally to healthy subjects.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Sep 2017

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Neratinib (Primary)
Indications Advanced breast cancer; Early breast cancer; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; Pharmacokinetics
Sponsors Puma Biotechnology

11 May 2012 Company added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.
11 May 2012 Actual patient number 56 added as reported by ClinicalTrials.gov.
11 Dec 2006 Status change

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com